Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea

Abu Rachman; Rani Sauriasari; Nadia Farhanah Syafhan; Pukovisa Prawiroharjo; Hindun Wilda Risni

doi:10.21109/kesmas.v17i4.6303

Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea

Abu Rachman, Rani Sauriasari, Nadia Farhanah Syafhan, Pukovisa Prawiroharjo, Hindun Wilda Risni

Abstract

The most prescribed antidiabetic drugs in Indonesian primary health care are metformin or a combination of metformin and sulfonylurea. Studies on metformin have shown various impacts on cognitive decline in patients with type 2 diabetes mellitus, whereas sulfonylurea has been shown to reduce this impact. This study aimed to compare the impacts of metformin and metformin-sulfonylurea on cognitive function and determine what factors affected it. This cross-sectional study was conducted at Pasar Minggu Primary Health Care involving 142 type 2 diabetes mellitus patients taking metformin or metformin-sulfonylurea for > 6 months and aged > 36 years. Cognitive function was assessed using the validated Montreal Cognitive Assessment Indonesian version. The effects of metformin and metformin-sulfonylurea on cognitive decline showed no significant difference, even after controlling for covariates (aOR = 1.096; 95% CI = 0.523–2.297; p-value = 0.808). Multivariate analysis showed age (OR = 4.131; 95% CI = 1.271–13.428; p-value = 0.018) and education (OR = 2.746; 95% CI = 1.196–6.305; p-value = 0.017) affected cognitive function. Since a lower education and older age are likely to cause cognitive decline, health professionals are encouraged to work with public health experts to address these risk factors for cognitive function.

Keywords

cognitive decline; cognitive function; diabetes mellitus; metformin; metformin-sulfonylurea

Full Text:

PDF

References

1. Kementerian Kesehatan Republik Indonesia. Tetap produktif, cegah dan atasi diabetes mellitus. Pusat Data dan Informasi Kementrian Kesehatan RI; 2020.

2. Varghese SM, Joy N, John AM, George G, Chandy GM, Benjamin AI. Sweet memories or not? A comparative study on cognitive impairment in diabetes mellitus. 2022; 10 (February): 1–7.

3. Hopkins R, Shaver K, Weinstock RS. Management of adults with diabetes and cognitive problems. Diabetes Spectr. 2016; 29 (4): 224–37.

4. Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Series diabetes and brain health 3 understanding multifactorial brain changes in type 2 diabetes : a biomarker perspective. 2021; 19.

5. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013; 36 (10): 2981–7.

6. Porter KM, Ward M, Hughes CF, O’Kane M, Hoey L, McCann A, et al. Hyperglycemia and metformin use are associated with b vitamin deficiency and cognitive dysfunction in older adults. J Clin Endocrinol Metab. 2019; 104 (10): 4837–47.

7. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021; 12: 1–13.

8. Zhang QQ, Li WS, Liu Z, Zhang HL, Ba YG, Zhang RX. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes. Medicine (Baltimore). 2020; 99 (10): e19378.

9. Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney memory and ageing study. Diabetes Care. 2020; 43 (11): 2691–701.

10. Picone P, Nuzzo D, Caruana L, Messina E, Barera A, Vasto S, et al. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin’s effect. Biochim Biophys Acta - Mol Cell Res. 2015; 1853 (5): 1046–59.

11. Lee AK, Rawlings AM, Lee CJ, Gross AL, Huang ES, Sharrett AR, et al. Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia. 2018; 61 (9): 1956–65.

12. Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications. Int J Mol Sci. 2018; 19 (11): 3306.

13. Olivari BS, Baumgart M, Taylor CA, McGuire LC. Population measures of subjective cognitive decline: a means of advancing public health policy to address cognitive health. Alzheimer’s Dement Transl Res Clin Interv. 2021; 7 (1).

14. Ogston SA, Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of sample size in health studies. Biometrics. 1991; 47 (1): 347.

15. Wu CY, Ouk M, Wong YY, Anita NZ, Edwards JD, Yang P, et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer’s disease, and the role APOE carrier status. Alzheimer’s Dement. 2020; 16 (12): 1663–73.

16. Perkumpulan Endokrinologi Indonesia. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2015. PB Perkeni. 2020; 46.

17. Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, del Campo N, et al. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc. 2015; 16 (9): 731–9.

18. Husein N, Lumempouw S, Ramli Y, Herqutanto. Montreal cognitive assessment versi Indonesia mocaina untuk skrining gangguan fungsi kognitif. Neurona. 2010; 27 (4).

19. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695–9.

20. Ginting H, Näring G, Van Der Veld WM, Srisayekti W, Becker ES. Validating the beck depression inventory-II in Indonesia’s general population and coronary heart disease patients. Int J Clin Heal Psychol. 2013; 13 (3): 235–42.

21. Cahyadi H, Prayitno A, Setiawan E. Reliability and validity of adherence to refill and medication scale (ARMS) in Indonesian geriatric population with diabetes; 2015.

22. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports. 2019; 92 (2): 117–22.

23. Soraya IA, Sauriasari R, Prawiroharjo P, Risni HW. The association between adherence to oral antihyperglycemic agent and HbA1c level. Pharm Sci Res. 2022; 9 (2): 93–101.

24. Sohn D, Shpanskaya K, Lucas JE, Petrella JR, Saykin AJ, Tanzi RE, et al. Sex differences in cognitive decline in subjects with high likelihood of mild cognitive impairment due to Alzheimer’s disease. Sci Rep. 2018; 8 (1): 7490.

25. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010; 75 (10): 889 LP – 897.

26. Soh Y, Lee DH, Won CW. Association between vitamin B12 levels and cognitive function in the elderly Korean population. Medicine (Baltimore). 2020 ;99 (30): e21371.

27. Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, et al. Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8 (12): 798.

28. Silverman JM, Schmeidler J, Lee PG, Alexander NB, Beeri MS, Guerrero-Berroa E, et al. Associations of hemoglobin A1c with cognition reduced for long diabetes duration. Alzheimer’s Dement Transl Res Clin Interv. 2019; 5: 926–32.

29. Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA1c, diabetes and cognitive decline: the English longitudinal study of ageing. Diabetologia. 2018; 61 (4): 839–48.

30. Vijayakumar T, Sirisha G, Begam F. Mechanism linking cognitive impairment and diabetes mellitus. Eur J Appl Sci. 2012; 4 (1): 1–05.

31. Vijayakumar PRA. Comparison of different classes of oral antidiabetic. 2019; 10 (7): 3455–60.

32. Hussien NR, Al-Naimi MS, Rasheed HA, Al-Kuraishy HM, Ali AG. Sulfonylurea and neuroprotection: the bright side of the moon. J Adv Pharm Technol Res. 2018; 9 (4): 120–3.

33. Lövdén M, Fratiglioni L, Glymour MM, Lindenberger U, Tucker-Drob EM. Education and cognitive functioning across the life span. Psychol Sci Public Interes. 2020; 21 (1): 6–41.

34. Jansen MG, Geerligs L, Claassen JAHR, Overdorp EJ, Brazil IA, Kessels RPC, et al. Positive effects of education on cognitive functioning depend on clinical status and neuropathological severity. Front Hum Neurosci. 2021; 15: 1–10.

35. Kartikasari D, Ariwinanti D, Hapsari A. Gambaran pengetah kesehat reproduksi siswa SMK Wisnuwardhana Kota Malang. Preventia : The Indonesian Journal of Public Health. 2019; 4 (1): 34–41.

36. Paul KC, Ling C, Lee A, To TM, Cockburn M, Haan M, et al. Cognitive decline, mortality, and organophosphorus exposure in aging Mexican Americans. Environ Res. 2018; 160: 132–9.

37. Leibson CL, Long KH, Ransom JE, Roberts RO, Hass SL, Duhig AM, et al. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population‐based study. Alzheimer’s Dement. 2015; 11 (8): 917–32.

38. Sørensen M, Groven KS, Gjelsvik B, Almendingen K, Garnweidner-Holme L. The roles of healthcare professionals in diabetes care: a qualitative study in Norwegian general practice. Scand J Prim Health Care. 2020; 38 (1): 12–23.

39. Akbar JM, Gondodiputro S, Raksanagara AS. Elderly satisfaction on chronic disease management program at public health center, Bandung City, West Java, Indonesia. Int J Integr Heal Sci. 2020; 8 (1): 14–21.

40. Fatmah F. Training program to support posbindu cadre knowledge and community health centre staff in the Geriatric Nutrition Service. ASEAN J Community Engagem. 2020; 4 (2): 500–18.

DOI: http://dx.doi.org/10.21109/kesmas.v17i4.6303